Ingrezza (Valbenazine)
What is a Generic Drug?
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Coming Soon – Save up to 85%
Sign up to get exclusive coupon discounts and be the first to be notified when we have this product available.
Prescription Required
-
Product Details
Description
Ingrezza (valbenazine) is prescribed to adults to treat tardive dyskinesia and chorea due to Huntington’s disease.
Ingrezza is available in 40 mg, 60 mg, and 80 mg capsules and Sprinkle capsules for oral administration.
Fact Table
Formula
C24H38N2O4
License
US FDA
Bioavailability
49% (approximate)
Legal status
Prescription only
Chemical Name
(2R,3S,11bR)-2-(4-Methylphenyl)sulfanyl-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinoline-8-carboxylic acid methyl ester
Elimination half-life
15 to 22 hours
Dosage (Strength)
40 mg, 80 mg capsules
Pregnancy
Consult a doctor
Brands
Ingrezza
Protein binding
99%
PubChem CID
54727394
MedlinePlus
a617034
ChEBI
CHEBI:134727
ATC code
N07XX13
DrugBank
DB11809
KEGG
D10854
Routes of administration
Oral
Directions
Take Ingrezza exactly as your doctor has prescribed.
Your doctor will determine an appropriate treatment regimen for you, including Ingrezza dosage.
Ingrezza capsules should be stored between 15°C and 30°C (59°F and 86°F). Ingrezza Sprinkle should be stored between 20°C and 25°C (68°F and 77°F).
Keep medications away from children.
For further instructions for use, you may refer to the medication guide that comes with your Ingrezza prescription.
Reach out to your doctor or pharmacist about any questions or concerns you have.
Ingredients
The active ingredient in Ingrezza is valbenazine.
Inactive ingredients in Ingrezza capsules include hypromellose, isomalt, magnesium stearate, pregelatinized starch, and silicified microcrystalline cellulose. The capsule shells contain candurin silver fine, FD&C Blue#1, FD&C Red#40, and gelatin.
Inactive ingredients in Ingrezza Sprinkle include silicified microcrystalline cellulose, isomalt, pregelatinized maize starch, hypromellose, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, gelatin, and candurin silver fine.
Contraindications
Patients with an allergy to valbenazine or to any of the other ingredients in Ingrezza capsules or Ingrezza Sprinkle should not take the medication.
Cautions
- Ingrezza contains the following FDA Boxed Warning:
- “Increases the risk of depression and suicidal thoughts and behavior in patients with Huntington’s disease
- Balance risks of depression, and suicidal ideation and behavior with the clinical need for treatment of chorea when considering the use of Ingrezza or Ingrezza Sprinkle
- Monitor patients for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior
- Inform patients, caregivers, and families of the risk of depression and suicidal ideation and behavior and instruct them to report behaviors of concern promptly to the treating physician
- Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation”
- Before you begin treatment with Ingrezza, talk to your doctor about:
- All the prescription and over-the-counter medications you take
- Your allergies
- Your current health problems and past medical history
- Your pregnancy or breastfeeding status
- Ingrezza can cause harm to an unborn baby
- Breastfeeding is not recommended while taking Ingrezza
- Ingrezza contains the following warnings and precautions:
- Depression and suicidal ideation and behavior in patients who have Huntington’s disease
- Hypersensitivity, including angioedema (swelling)
- Excessive sleepiness/sedation
- QT prolongation
- Neuroleptic malignant syndrome
- Parkinsonism
Side Effects
Excessive sleepiness is the most common side effect of Ingrezza in patients with tardive dyskinesia. Excessive sleepiness, lethargy, sedation, hives, rash, and problems with sleep are common side effects of Ingrezza in patients with chorea due to Huntington’s disease. Other side effects may also occur.
Contact your doctor right away if you develop side effects that bother you or won’t go away.
Searching for a competitive Ingrezza price? With a valid prescription, you can buy Ingrezza right here!
Reference
Ingrezza. San Diego, CA: Neurocrine Biosciences, Inc.; 2024.
IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.Product Code : 14942
-
Product Reviews
